Effect of 2nd Gen TKI in CML
Effect of Prior Therapy With Nilotinib or Dasatinib on the Outcome After Allogeneic Stem Cell Transplantation for Patients With Chronic Myeloid Leukaemia
Sponsor: European Society for Blood and Marrow Transplantation
A observational or N/A phase clinical study on Myeloid Leukemia, Chronic, this trial is completed. The trial is conducted by European Society for Blood and Marrow Transplantation and has accumulated 10 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2024 — Jul 2024 [monthly]
Completed
-
Nov 2021 — Mar 2024 [monthly]
Completed
▶ Show 5 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Completed
-
Sep 2019 — Jan 2021 [monthly]
Completed
Status: Unknown Status → Completed
-
Jun 2018 — Sep 2019 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Unknown Status NA
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Society for Blood and Marrow Transplantation
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .